{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:52:50Z","timestamp":1777564370820,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40263-022-00923-3","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T03:23:26Z","timestamp":1653881006000},"page":"605-616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Olanzapine\/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain"],"prefix":"10.1007","volume":"36","author":[{"given":"Madeline M.","family":"Corrao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1481-8682","authenticated-orcid":false,"given":"Leigh Anne","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,30]]},"reference":[{"key":"923_CR1","unstructured":"Hirschfeld RMA, Bowden CL, Gitlin MJ, et al. Practice guideline for the treatment of patients with bipolar disorder. 2nd ed. Washington, DC: American Psychiatric Association; 2010. p. 82."},{"key":"923_CR2","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association Practice. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. https:\/\/doi.org\/10.1176\/appi.books.9780890424841. Accessed 20 Sept 2021.","DOI":"10.1176\/appi.books.9780890424841"},{"key":"923_CR3","unstructured":"Eli Lilly and Company. Olanzapine prescribing guide. 2006. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/020592s042s043,021086s022s023,021253s026lbl.pdf. Accessed 26 Apr 2022."},{"issue":"4","key":"923_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.euroneuro.2006.09.005","volume":"17","author":"JM Haro","year":"2007","unstructured":"Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007;17(4):235\u201344. https:\/\/doi.org\/10.1016\/j.euroneuro.2006.09.005.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"12","key":"923_CR5","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Rosenheck RA, Davis SM, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209\u201323.","journal-title":"N Engl J Med"},{"issue":"9618","key":"923_CR6","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(08)60486-9.","journal-title":"Lancet"},{"key":"923_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/POR.S64973","volume":"6","author":"M Takahashi","year":"2015","unstructured":"Takahashi M, Nakahara N, Fujikoshi S, Iyo M. Remission, response, and relapse rates in patients with acute schizophrenia treated with olanzapine monotherapy or other atypical antipsychotic monotherapy: 12-month prospective observational study. Pragmat Obs Res. 2015;6:39\u201346. https:\/\/doi.org\/10.2147\/POR.S64973.","journal-title":"Pragmat Obs Res."},{"issue":"04","key":"923_CR8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.4088\/JCP.10m06497","volume":"73","author":"RL Berkowitz","year":"2012","unstructured":"Berkowitz RL, Patel U, Ni Q, Parks JJ, Docherty JP. The impact of the clinical antipsychotic trials of intervention effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state. J Clin Psychiatry. 2012;73(04):498\u2013503. https:\/\/doi.org\/10.4088\/JCP.10m06497.","journal-title":"J Clin Psychiatry"},{"issue":"9896","key":"923_CR9","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(13)60733-3.","journal-title":"Lancet"},{"issue":"2","key":"923_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jecm.2012.01.007","volume":"4","author":"S-C Chang","year":"2012","unstructured":"Chang S-C, Lu M-L. Metabolic and cardiovascular adverse effects associated with treatment with antipsychotic drugs. J Exp Clin Med. 2012;4(2):103\u20137. https:\/\/doi.org\/10.1016\/j.jecm.2012.01.007.","journal-title":"J Exp Clin Med"},{"issue":"1","key":"923_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2010","unstructured":"Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71\u201393. https:\/\/doi.org\/10.1093\/schbul\/sbp116.","journal-title":"Schizophr Bull"},{"key":"923_CR12","unstructured":"World Health Organization. Premature death among people with severe mental disorders. https:\/\/www.who.int\/mental_health\/management\/info_sheet.pdf. Accessed 20 Sept 2021."},{"key":"923_CR13","unstructured":"Alkermes, Inc.. Lybalvi (olanzapine and samidorphan) [prescribing information]. May 2021. Alkermes, Inc. https:\/\/www.lybalvi.com\/lybalvi-prescribing-information.pdf. Accessed 26 Apr 2021."},{"key":"923_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.schres.2017.10.014","volume":"195","author":"BL Silverman","year":"2018","unstructured":"Silverman BL, Martin W, Memisoglu A, DiPetrillo L, Correll CU, Kane JM. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. Schizophr Res. 2018;195:245\u201351. https:\/\/doi.org\/10.1016\/j.schres.2017.10.014.","journal-title":"Schizophr Res"},{"issue":"8","key":"923_CR15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2165\/00003495-200868080-00008","volume":"68","author":"ED Deeks","year":"2008","unstructured":"Deeks ED, Keating GM. Olanzapine\/fluoxetine. Drugs. 2008;68(8):1115\u201337. https:\/\/doi.org\/10.2165\/00003495-200868080-00008.","journal-title":"Drugs"},{"key":"923_CR16","unstructured":"Thomas K, Saadabadi A. Olanzapine. StatPearls. 2021. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532903\/. Accessed 8 Sept 2021."},{"issue":"9","key":"923_CR17","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1172\/JCI93362","volume":"127","author":"CC Lord","year":"2021","unstructured":"Lord CC, Wyler SC, Wan R, et al. The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C. J Clin Investig. 2021;127(9):3402\u20136. https:\/\/doi.org\/10.1172\/JCI93362.","journal-title":"J Clin Investig"},{"issue":"8","key":"923_CR18","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1096\/fj.12-208041","volume":"26","author":"TA Czyzyk","year":"2012","unstructured":"Czyzyk TA, Romero-Pic\u00f3 A, Pintar J, et al. Mice lacking \u03b4-opioid receptors resist the development of diet-induced obesity. FASEB J. 2012;26(8):3483\u201392. https:\/\/doi.org\/10.1096\/fj.12-208041.","journal-title":"FASEB J"},{"issue":"4","key":"923_CR19","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1096\/fj.09-143610","volume":"24","author":"TA Czyzyk","year":"2010","unstructured":"Czyzyk TA, Nogueiras R, Lockwood JF, et al. \u03ba-Opioid receptors control the metabolic response to a high-energy diet in mice. FASEB J. 2010;24(4):1151\u20139. https:\/\/doi.org\/10.1096\/fj.09-143610.","journal-title":"FASEB J"},{"key":"923_CR20","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Resistance to diet-induced obesity in \u03bc-opioid receptor-deficient mice. https:\/\/diabetes.diabetesjournals.org\/content\/54\/12\/3510.long. Accessed 21 Sept 2021.","DOI":"10.2337\/diabetes.54.12.3510"},{"issue":"10","key":"923_CR21","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1177\/0269881119856850","volume":"33","author":"JI Cunningham","year":"2019","unstructured":"Cunningham JI, Eyerman DJ, Todtenkopf MS, et al. Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates. J Psychopharmacol. 2019;33(10):1303\u201316. https:\/\/doi.org\/10.1177\/0269881119856850.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"923_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/JCP.0000000000000320","volume":"35","author":"MJ Shram","year":"2015","unstructured":"Shram MJ, Silverman B, Ehrich E, et al. Use of remifentanil in a novel clinical paradigm to characterize onset and duration of opioid blockade by samidorphan, a potent mu-receptor antagonsist. J Clin Psychopharmacol. 2015;35(3):242\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"923_CR23","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.2337\/diabetes.54.12.3510","volume":"54","author":"A Tabarin","year":"2005","unstructured":"Tabarin A, Diz-Chaves Y, Carmona MC, et al. Resistence to diet-induced obesity in mu-opioid receptor-deficient mice: evidence for a \u201cthrifty gene.\u201d Diabetes. 2005;54(12):3510\u20136.","journal-title":"Diabetes"},{"issue":"11","key":"923_CR24","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/jcph.1911","volume":"61","author":"L Sun","year":"2021","unstructured":"Sun L, Mills R, Sadler BM, Rege B. Population pharmacokinetics of olanzapine and samidorphan when administered in combination in healthy subjects and patients with schizophrenia. J Clin Pharmacol. 2021;61(11):1430\u201341.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"923_CR25","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.clinthera.2018.09.002","volume":"40","author":"L Sun","year":"2018","unstructured":"Sun L, McDonnell D, von Moltke L. Pharmacokinetics and short-term safety of ALKS 3831, a fixed-dose combination of olanazapine and samidorphan, in adult subjects with schizophrenia. Clin Ther. 2018;40(11):1845\u201354.","journal-title":"Clin Ther"},{"issue":"2","key":"923_CR26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.clinthera.2014.10.001","volume":"37","author":"R Turncliff","year":"2015","unstructured":"Turncliff R, Dipetrillo L, Sliverman B, Ehrich E. Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers. Clin Ther. 2015;37(2):338\u201348.","journal-title":"Clin Ther"},{"issue":"3","key":"923_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","volume":"37","author":"JT Callaghan","year":"1999","unstructured":"Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37(3):177\u201393. https:\/\/doi.org\/10.2165\/00003088-199937030-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"923_CR28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40268-019-00280-5","volume":"19","author":"V Kumar","year":"2019","unstructured":"Kumar V, Lu H, Hard M, von Moltke L. Characterization of the pharmacokinetics of samidorphan in healthy volunteers: absolute bioavailability and the effect of food and age. Drugs R D. 2019;19(3):277\u201387. https:\/\/doi.org\/10.1007\/s40268-019-00280-5.","journal-title":"Drugs R D."},{"key":"923_CR29","volume":"60","author":"L Sun","year":"2021","unstructured":"Sun L, von Moltke L, Yeo KR. Application of physiologically based pharmacokinetic modeling to predict the effect of renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination. Clin Pharmacokinet. 2021;60: 637647.","journal-title":"Clin Pharmacokinet"},{"key":"923_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/psp4.12488","volume":"9","author":"L Sun","year":"2020","unstructured":"Sun L, von Moltke L, Yeo KR. Physiologically-based pharmacokinetic modeling for predicting drug interactions of a combination of olanzapine and samidorphan. CPT Pharmacomet Syst Pharmacol. 2020;9:106\u201314.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"923_CR31","unstructured":"NORC. One-third of Americans have received an opioid prescription in the past two years. https:\/\/www.norc.org\/NewsEventsPublications\/PressReleases\/Pages\/one-third-of-americans-have-received-an-opioid-prescription-in-the-past-two-years.aspx. Accessed 16 Sept 2021."},{"issue":"4","key":"923_CR32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3122\/jabfm.2017.04.170112","volume":"30","author":"MA Davis","year":"2017","unstructured":"Davis MA, Lin LA, Liu H, Sites BD. Prescription opioid use among adults with mental health disorders in the United States. J Am Board Fam Med. 2017;30(4):407\u201317. https:\/\/doi.org\/10.3122\/jabfm.2017.04.170112.","journal-title":"J Am Board Fam Med"},{"issue":"6","key":"923_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1176\/appi.ajp.2018.18030280","volume":"176","author":"WF Martin","year":"2019","unstructured":"Martin WF, DiPetrillo L. Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. Am J Psychiatry. 2019;176(6):457\u201367.","journal-title":"Am J Psychiatry"},{"key":"923_CR34","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12769","author":"SG Potkin","year":"2020","unstructured":"Potkin SG, Kunovac J, Silverman BL, et al. Efficacy and safety of a combination of olanzapine and samidorphan in adult patients with an acute exacerbation of schizophrenia: outcomes from the randomized, phase 3 ENLIGHTEN-1 study. J Clin Psychiatry. 2020. https:\/\/doi.org\/10.4088\/JCP.19m12769.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"923_CR35","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1176\/appi.ajp.2020.19121279","volume":"177","author":"CU Correll","year":"2020","unstructured":"Correll CU, Newcomer JW, Silverman B, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. AJP. 2020;177(12):1168\u201378. https:\/\/doi.org\/10.1176\/appi.ajp.2020.19121279.","journal-title":"AJP"},{"key":"923_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.schres.2021.04.009","volume":"232","author":"RS Kahn","year":"2021","unstructured":"Kahn RS, Silverman BL, DiPetrillo L, et al. A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: results from the ENLIGHTEN-2 long-term extension. Schizophr Res. 2021;232:45\u201353. https:\/\/doi.org\/10.1016\/j.schres.2021.04.009.","journal-title":"Schizophr Res"},{"key":"923_CR37","unstructured":"ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/. Accessed 22 Mar 2022."},{"key":"923_CR38","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12786","author":"MF Brunette","year":"2020","unstructured":"Brunette MF, Correll CU, O\u2019Malley SS, et al. Olanzapine plus samidorphan (ALKS 3831) in schizophrenia and comorbid alcohol use disorder: a phase 2, randomized clinical trial. J Clin Psychiatry. 2020. https:\/\/doi.org\/10.4088\/JCP.19m12786.","journal-title":"J Clin Psychiatry"},{"issue":"19","key":"923_CR39","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","volume":"264","author":"DA Regier","year":"1990","unstructured":"Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264(19):2511\u20138.","journal-title":"JAMA"},{"issue":"1","key":"923_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1600-0447.2012.01911.x","volume":"127","author":"H J\u00f3nsd\u00f3ttir","year":"2013","unstructured":"J\u00f3nsd\u00f3ttir H, Opjordsmoen S, Birkenaes AB, et al. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2013;127(1):23\u201333. https:\/\/doi.org\/10.1111\/j.1600-0447.2012.01911.x.","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"923_CR41","doi-asserted-by":"publisher","first-page":"775","DOI":"10.4088\/JCP.10m06320","volume":"72","author":"RM Jones","year":"2011","unstructured":"Jones RM, Lichtenstein P, Grann M, L\u00e5ngstr\u00f6m N, Fazel S. Alcohol use disorders in schizophrenia: a national cohort study of 12,653 patients. J Clin Psychiatry. 2011;72(6):775\u20139. https:\/\/doi.org\/10.4088\/JCP.10m06320.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"923_CR42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/13651501.2017.1291839","volume":"21","author":"A Hasan","year":"2017","unstructured":"Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia: a short version for primary care. Int J Psychiatry Clin Pract. 2017;21(2):82\u201390. https:\/\/doi.org\/10.1080\/13651501.2017.1291839.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"10","key":"923_CR43","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.4088\/JCP.13m08838","volume":"76","author":"AI Green","year":"2015","unstructured":"Green AI, Brunette MF, Dawson R, et al. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. J Clin Psychiatry. 2015;76(10):1359\u201365. https:\/\/doi.org\/10.4088\/JCP.13m08838.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"923_CR44","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s00213-004-1881-z","volume":"174","author":"IL Petrakis","year":"2004","unstructured":"Petrakis IL, O\u2019Malley S, Rounsaville B, et al. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology. 2004;174(2):300. https:\/\/doi.org\/10.1007\/s00213-004-1881-z.","journal-title":"Psychopharmacology"},{"issue":"10","key":"923_CR45","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1111\/acer.13849","volume":"42","author":"SS O'Malley","year":"2018","unstructured":"O\u2019Malley SS, Todtenkopf MS, Du Y, et al. Effects of the opioid system modulator, samidorphan, on measures of alcohol consumption and patient-reported outcomes in adults with alcohol dependence. Alcohol Clin Exp Res. 2018;42(10):2011\u201321.","journal-title":"Alcohol Clin Exp Res"},{"key":"923_CR46","unstructured":"ScienceDirect. Factors affecting smoking in schizophrenia. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0010440X01155100?via%3Dihub. Accessed 15 Sept 2021."},{"issue":"2","key":"923_CR47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/00004714-200304000-00003","volume":"23","author":"JA Carrillo","year":"2003","unstructured":"Carrillo JA, Herr\u00e1iz AG, Ramos SI, Gervasini G, Vizca\u00edno S, Ben\u00edtez J. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol. 2003;23(2):119\u201327.","journal-title":"J Clin Psychopharmacol"},{"key":"923_CR48","unstructured":"ScienceDirect. Smoking and schizophrenia. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/092099649290024Y?via%3Dihub. Accessed 15 Sept 2021."},{"issue":"3","key":"923_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004216","volume":"4","author":"Y Tsuda","year":"2014","unstructured":"Tsuda Y, Saruwatari J, Yasui-Furukori N. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open. 2014;4(3): e004216. https:\/\/doi.org\/10.1136\/bmjopen-2013-004216.","journal-title":"BMJ Open"},{"key":"923_CR50","unstructured":"The Top 200 of 2019. https:\/\/clincalc.com\/DrugStats\/Top200Drugs.aspx. Accessed 29 Sept 2021."},{"issue":"6","key":"923_CR51","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/schbul\/sbu030","volume":"40","author":"Y Mizuno","year":"2014","unstructured":"Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, et al. Pharmacological strategies to counteractn antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385\u2013402.","journal-title":"Schizophr Bull"},{"issue":"1","key":"923_CR52","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12888-016-1049-5","volume":"16","author":"VA de Silva","year":"2016","unstructured":"de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):341.","journal-title":"BMC Psychiatry"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00923-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00923-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00923-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T12:12:15Z","timestamp":1654258335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00923-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,30]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["923"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00923-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,30]]},"assertion":[{"value":"13 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors received no financial support for the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declaration of conflict of interest is as follows: Madeline M. Corrao has nothing to disclose. Leigh Anne Nelson served on an advisory board for Sunovion and Janssen pharmaceutical companies. She has received research funding from Boehringer Ingelheim, Alkermes, Inc. She is also a consultant in the speaker\u2019s bureau of Alkermes Inc. for the following drugs: Aristada and Lybalvi. Alkermes, Inc. is the manufacturer of Lybalvi (olanzapine\/samidorphan).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Madeline M. Corrao conducted a literature analysis, wrote the paper, and completed revisions. Leigh Anne Nelson conceived the paper concept, conducted a literature analysis, edited the paper, submitted the paper, and is solely responsible for completing the revisions following peer review.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}